Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer
PUBLIC · OTLKAug 27, 2026•about 3 hours ago
Position
Secretary
Company
Outlook Therapeutics
Lawrence A. Kenyon
CranburyOtherBiotechnology
Description
On August 27, 2026, Outlook Therapeutics, Inc. appointed Kevin Lundquist as the Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer. This appointment follows the mutual agreement for Lawrence A
Company Information
Company
Outlook Therapeutics
Location
7 Clarke Dr
Cranbury, New Jersey, United States
About
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
Don't miss Outlook Therapeutics's next move
Get an email the moment Outlook Therapeutics changes its leadership, hires an exec, or expands, usually minutes after it happens.
CranburyOtherBiotechnology